Redpin Therapeutics is a privately-held, preclinical stage gene therapy company based in New York City. We are developing a proprietary chemogenetics platform for targeted cell therapies that address currently intractable diseases of the nervous system. Our approach integrates powerful principles from synthetic biology, gene therapy, and traditional pharmacotherapy.
Our science is based on the groundbreaking discovery and development of an ultrapotent ion channel-based chemogenetics platform that enables targeted cell activation or inhibition controlled by low doses of the anti-smoking drug varenicline (CHANTIX®).
Company Details
- Address
- Currently Intractable Diseases Of The Nervous System. Our Approach Integrates Powerful Principles From Synthetic Biology
- Phone
- 9179719655
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- redpinrx.com
- Keywords
- Parsippany.
Redpin Therapeutics Questions
Redpin Therapeutics's helpline number is 9179719655
Redpin Therapeutics's website is redpinrx.com
Redpin Therapeutics's LinkedIn profile is https://www.linkedin.com/company/redpin-therapeutics
Redpin Therapeutics's industry is
Pharmaceutical Manufacturing
Redpin Therapeutics's top competitors are
Stealth Mode Biotech,
Gensight Biologics,
Memorial Sloan Kettering Cancer Center,
Anvesana,
Selecta Biosciences,
Curamir Therapeutics, Inc.,
Ssi Strategy,
Invitro Cell Research, Llc,
Brammer Bio,
Sg3 Ventures Llc.
Redpin Therapeutics's categories are Pharmaceutical Manufacturing
